SIRTI and Adaptive Muscle Growth
SIRTI and Adaptive Muscle Growth
批准号:
9243930
负责人:
Simon Schenk
金额:
$20.48万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2019-02-28
关键词:
AblationAcetylationAcquired Immunodeficiency SyndromeActivities of Daily LivingAcuteAddressAgingAntigensAreaAttenuatedBiogenesisCachexiaChronic DiseaseClinicalComplexCytoplasmic GranulesDeacetylaseDeacetylationDevelopmentDiseaseDoseElectric StimulationEukaryotic Initiation FactorsFRAP1 geneFiberGenetic TranslationGrowthHIVHealthHindlimbHumanInterventionIntuitionKidney DiseasesKnock-outKnowledgeLeftLife StyleLinkLoxP-flanked alleleLysineMalignant NeoplasmsMeasuresModelingMolecularMorbidity - disease rateMusMuscleMuscle CellsMuscle FibersMuscle functionMuscular AtrophyMutateMyopathyNuclear ImportPathway interactionsPhosphorylationProtein AcetylationProtein BiosynthesisProtein KinaseProteinsProteomicsQuality of lifeRNA-Binding ProteinsRegulationResearchRibosomal Protein S6 KinaseRibosomesRiskSIRT1 geneSideSignal TransductionSignaling MoleculeSirolimusSkeletal MuscleStimulusStudy modelsT-LymphocyteTherapeuticThinkingWorkbaseclinically relevantcytotoxicdisorder riskexperimental studyin vivoin vivo Modelinnovationinsightmortalitymouse modelmuscle formnovelnovel therapeuticsoverexpressionpredictive modelingprotein phosphatase inhibitor-2reduced muscle strengthresponseskeletalskeletal disorderskeletal muscle growthskeletal muscle wastingtargeted treatmenttherapy development
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Skeletal muscle mass and function are inversely associated with chronic disease risk and mortality.
Understanding the molecular mechanisms underlying the regulation of muscle growth and mass, particularly as
it relates to adaptive muscle growth, holds therapeutic promise. The long-term objective of this research is to
define the mechanisms underlying adaptive skeletal muscle growth. Currently, phosphorylation-based
signaling through the mammalian target of rapamycin complex 1 (mTORC1) pathway is considered the
principal mechanism underlying adaptive muscle growth (i.e. growth changes in response to loading). We
believe however, that reversible lysine acetylation of proteins comprising the mTORC1 complex and/or its
downstream targets provide an additional level of control of adaptive growth. Accordingly, for this application
our primary objective is to elucidate the importance of sirtuin 1 (SIRT1), a well-described protein deacetylase,
to adaptive muscle growth and to identify potential growth-related signaling molecules regulated by SIRT1. Our
central hypothesis is that SIRT1 restricts protein synthesis and adaptive muscle growth through coordinated
deacetylation of S6K1 and downstream targets that control mRNA translation. This innovative hypothesis is
contrary to current thinking contending that SIRT1 is a positive regulator of muscle growth. To address our
hypothesis, our approach will be to measure skeletal muscle protein synthesis, mass and fiber area, in
response to adaptive growth stimuli in novel mouse models in which we have manipulated SIRT1 activity in
skeletal muscle. Our model predicts that reducing SIRT1 activity will lead to an enhanced adaptive growth
response, in concert with increased acetylation of targets of SIRT1. Specifically, Aim #1 will elucidate the
contribution of SIRT1 to the adaptive growth response in skeletal muscle, whilst Aim #2 will determine whether
acetylation of SIRT1 targets underlies differences in the growth response. Altogether, these studies will
broaden our understanding of the contribution of SIRT1 and acetylation to skeletal muscle growth in response
to loading. Ultimately, we expect this will have wide-reaching impact on the development of therapies to treat
not only muscle atrophy, but also other diseases of skeletal muscle.!
!
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanistic study of skeletal muscle proteolysis induced by breast cancer-secreted extracellular vesicles
-
批准号:10704327
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2022
-
负责人:Simon Schenk
-
依托单位:
Acetylation and contraction-mediated glucose uptake
-
批准号:10490253
-
项目类别:
-
资助金额:$20.26万
-
财政年份:2021
-
负责人:Simon Schenk
-
依托单位:
Acetylation and contraction-mediated glucose uptake
-
批准号:10155065
-
项目类别:
-
资助金额:$24.56万
-
财政年份:2021
-
负责人:Simon Schenk
-
依托单位:
SIRT1 and muscle insulin sensitivity
-
批准号:8516958
-
项目类别:
-
资助金额:$28.54万
-
财政年份:2012
-
负责人:Simon Schenk
-
依托单位:
SIRT1 and muscle insulin sensitivity
-
批准号:8918077
-
项目类别:
-
资助金额:$15.5万
-
财政年份:2012
-
负责人:Simon Schenk
-
依托单位:
SIRT1 and muscle insulin sensitivity
-
批准号:8372767
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2012
-
负责人:Simon Schenk
-
依托单位:
SIRT1 and muscle insulin sensitivity
-
批准号:8706753
-
项目类别:
-
资助金额:$30.77万
-
财政年份:2012
-
负责人:Simon Schenk
-
依托单位:
SIRT1 and muscle insulin sensitivity
-
批准号:9084479
-
项目类别:
-
资助金额:$30.52万
-
财政年份:2012
-
负责人:Simon Schenk
-
依托单位:
海外基金